Engraftment Syndrome Emerges as the Main Cause of Transplant-Related Mortality in Pediatric Patients Receiving Autologous Peripheral Blood Progenitor Cell Transplantation
- 1 August 2004
- journal article
- Published by Wolters Kluwer Health in Journal of Pediatric Hematology/Oncology
- Vol. 26 (8) , 492-496
- https://doi.org/10.1097/01.mph.0000130217.41531.fb
Abstract
The authors examined data from 166 children who received autologous peripheral blood progenitor cell (PBPC) transplantation to ascertain the incidence of early transplant-related mortality (TRM) and the contributing risk factors. Eleven patients (6.6%) (6 boys, 5 girls) died within 180 days following PBPC infusion. The median age was 4 years (range 2–17). The overall probability of TRM was 6.9 ± 2% at day +180. On univariate analysis, the status of disease at transplantation (complete remission vs. not in complete remission) was identified as the only pretransplant significant predicting factor for TRM (14% of patients who were not in complete remission died within 180 days after PBPC infusion, whereas only 2% of patients in complete remission died) (relative risk [RR] 1.13, 95% confidence interval [CI] 1.01–1.26, P = 0.01). Age, gender, conditioning, and number of CD34+ cells infused were not significantly associated with TRM. In the postinfusion phase, patients who developed multiorgan dysfunction during the neutropenic period, especially when the lung was the first failing organ (RR 16.1, 95% CI 7.16–36.18, P = 0.0001), and those with engraftment syndrome (RR 2.81, 95% CI 1.49–5.24, P = 0.001) had an increased risk for TRM. On multivariate analysis, development of engraftment syndrome was the only significant variable that influenced TRM. In conclusion, the authors found for the first time that engraftment syndrome emerges as the main cause of TRM after autologous PBPC transplantation in children with malignancies.Keywords
This publication has 27 references indexed in Scilit:
- Transplant-related toxicity and mortality: an AIEOP prospective study in 636 pediatric patients transplanted for acute leukemiaBone Marrow Transplantation, 2002
- Bone Marrow Transplant Patients With Life-Threatening Organ Failure: When Should Treatment Stop?Journal of Clinical Oncology, 1999
- Risk factors for hepatic veno-occlusive disease after bone marrow transplantation: retrospective analysis of 137 cases at a single institutionBone Marrow Transplantation, 1997
- Treatment-related mortality in 1000 consecutive patients receiving high-dose chemotherapy and peripheral blood progenitor cell transplantation in community cancer centersBone Marrow Transplantation, 1997
- Peripheral-blood stem-cell transplantation versus autologous bone marrow transplantation in Hodgkin's and non-Hodgkin's lymphomas: a new matched-pair analysis of the European Group for Blood and Marrow Transplantation Registry Data. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.Journal of Clinical Oncology, 1997
- Pulmonary Complications of Bone Marrow TransplantationChest, 1996
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- Etiology and outcome of diarrhea after marrow transplantation: A prospective studyGastroenterology, 1994
- High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.Journal of Clinical Oncology, 1993
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993